Skip to main content
Evidence Snapshot

Alpha-2A adrenergic receptor

CHEMBL4744 SINGLE PROTEIN Bos taurus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4744
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Alpha-2A adrenergic receptor as ChEMBL target CHEMBL4744, mapped to UniProt Q28838. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Alpha-2A adrenergic receptor
SINGLE PROTEIN · Bos taurus
As of 2026-09-14
ChEMBL target ID
CHEMBL4744
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q28838
Alpha-2A adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Alpha-2A adrenergic receptor matters

As of 2026-09-14

Alpha-2A adrenergic receptor is reviewed as Alpha-2A adrenergic receptor (UniProt Q28838); the current evidence base includes 6 approved drugs, 133 compounds, and 18 assays, with lead potency reaching pChEMBL 9.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 133 compounds, and 18 assays for this target. The dominant activity type is KI. CHEMBL48603 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL48603 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Alpha-2A adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q28838, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

133
Total Compounds
18
Total Assays
6
Approved Drugs
IC50: 58.0, KI: 94.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL48603
 9.1 Ki —
No preferred name
CHEMBL597
 9.0 Ki Approved
No preferred name
CHEMBL48558
 8.9 Ki —
No preferred name
CHEMBL10316
 8.8 Ki Clinical
No preferred name
CHEMBL762
 8.8 Ki Approved

Approved Drugs

Structure Compound First Approval
OXYMETAZOLINE
CHEMBL762
 1986
PRAZOSIN
CHEMBL2
 1976
CLONIDINE
CHEMBL134
 1974
PHENTOLAMINE
CHEMBL597
 1952
MIANSERIN
CHEMBL6437
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4744